NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are ad.
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of Cara Therapeutics, Inc. (NasdaqCM: CARA) and Tvardi Therapeutics, Inc. Pursuant to the terms of the agreement, upon completion of the Merger, Cara shareholders are expected to own approximately 17.0% of the combined company. KSF is seeking to determine whether the merger and the process that led to it are ad.
STAMFORD, Conn., Dec. 27, 2024 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq: CARA) (the “ Company ”), today announced that a 1-for-12 reverse stock split of its outstanding shares of common stock and reduction in the total number of authorized shares of its common stock from 200,000,000 to 16,666,667 will be effective as of 5:00 p.m. Eastern Time on Monday, December 30, 2024.
Alessia's fans will experience a behind-the-scenes look at the creative process for her Love & Hyperbole album trailer through an episodic series, brought to life by Lenovo's smarter technology and Intel's cutting-edge processors. LOS ANGELES , Dec. 19, 2024 /PRNewswire/ -- In their sixth year of collaborating with globally-renowned artists to bring their creative visions to life, Lenovo, Intel, and Universal Music Group For Brands (UMGB), announced a new partnership with singer/songwriter and GRAMMY® Award-winning artist Alessia Cara.
Proposed Merger to create a Nasdaq-listed, clinical-stage biopharmaceutical company developing novel treatments targeting STAT3 to treat fibrosis-driven diseases
NEW YORK , Dec. 18, 2024 /PRNewswire/ -- Monteverde & Associates PC (the "M&A Class Action Firm"), has recovered millions of dollars for shareholders and is recognized as a Top 50 Firm by ISS Securities Class Action Services Report. We are headquartered at the Empire State Building in New York City and are investigating Cara Therapeutics, Inc. (NASDAQ: CARA ), relating to the proposed merger with Tvardi Therapeutics, Inc. Under the terms of the agreement, Cara Therapeutics stockholders are expected to own approximately 17.0% of the combined company.
Shares of Cara Therapeutics Inc CARA tanked in early trading on Thursday, with the Dow shedding more than 100 points.
Cara Therapeutics said on Wednesday it will discontinue a mid-to-late stage study for a neurological condition that causes itching after its experimental drug did not demonstrate a meaningful clinical benefit compared to placebo.
Cara Therapeutics (CARA) reported a quarterly loss of $0.56 per share, which was higher than the Zacks Consensus Estimate of a loss of $0.38 per share. This is compared to a loss of $0.49 per share in the same quarter last year.
Cara Therapeutics, Inc. (Nasdaq: CARA), a development-stage biopharmaceutical company leading a new treatment paradigm to improve the lives of patients suffering from pruritus, today announced that Christopher Posner, President and Chief Executive Officer, will present at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9, 2024, at 8:40 a.m. EDT.